60 likes | 205 Views
POISE-2. P eri O perative IS chemic E valuation- 2 Trial. Clonidine in Patients Having Noncardiac Surgery. Daniel I. Sessler, Department of O UTCOMES R ESEARCH , Cleveland Clinic, on behalf of POISE-2 Investigators. Background. Post-op MI leading cause of post-op death
E N D
POISE-2 PeriOperative ISchemic Evaluation-2 Trial Clonidine in Patients Having Noncardiac Surgery Daniel I. Sessler, Department of OUTCOMES RESEARCH, Cleveland Clinic, on behalf of POISE-2 Investigators
Background Post-op MI leading cause of post-op death 8% of surgical inpatients >45 years 10% 30-day mortality Safe prophylactic strategies unknown beta blockers decrease risk of MI but increase risk of stroke and mortality Clonidine decreases central sympathetic outflow analgesic anti-inflammatory Hypothesis: clonidine reduces composite MI & death after noncardiac surgery
Methods Blinded 2 x 2 factorial randomized trial low-dose clonidine vs. placebo 0.2 mg/day X 72 hours, started just before surgery Non-cardiac inpatient surgery, age >45 years history of CAD, stroke, PVD, having vascular surgery, or 3 of 9 risk factors 10,010 patients at 135 centers in 23 countries Primary outcome composite of death and adjudicated MI at 30 days
Clinically important hypotension Independent predictor of MI HR 1.37 (95% CI, 1.16-1.62) Most common during surgery Median intraoperative duration – 15 minutes Duration longer on ward Median postoperative duration – 180 minutes
Conclusions Perioperative MIs are common and lethal Clonidine does not reduce postop MI or death Promotes clinically important hypotension increases nonfatal cardiac arrest Preventing MIs may be balance between decreasing HR (minimizing oxygen demand) avoiding hypotension (ensuring oxygen supply) New strategies are needed Low-dose clonidine should not be given to patients having noncardiac surgery in an effort to reduce perioperative mortality or MI